PD-1 Inhibitor Effective for Localized Mismatch Repair-Deficient CRC

Neoadjuvant treatment with a PD-1 inhibitor is effective for localized mismatch repair-deficient colorectal cancer. Among 73 patients, 84.9% achieved an objective response per radiologic assessment, including 23.3% and 61.6% with complete response and partial response, respectively.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ